	US 11,737,999 B2
	Amino acid compositions and methods for the treatment of post-acute sequelae of COVID-19
Revati Wani, Medford, MA (US); Alison Schecter, Newton Centre, MA (US); Michael Hamill, Wellesley, MA (US); Margaret Koziel, Needham, MA (US); Matthew Russell, Wellesley, MA (US); Karim Azer, Needham, MA (US); Karen Lavery, Franklin, MA (US); and Joel Pradines, Watertown, MA (US)
Assigned to AXCELLA HEALTH INC., Cambridge, MA (US)
Filed by AXCELLA HEALTH INC., Cambridge, MA (US)
Filed on Jul. 25, 2022, as Appl. No. 17/872,749.
Claims priority of provisional application 63/271,665, filed on Oct. 25, 2021.
Claims priority of provisional application 63/225,850, filed on Jul. 26, 2021.
Prior Publication US 2023/0038163 A1, Feb. 9, 2023
Int. Cl. A61K 31/198 (2006.01); A61P 21/00 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61K 31/4172 (2006.01)

CPC A61K 31/198 (2013.01) [A61K 31/4172 (2013.01); A61P 21/00 (2018.01); A61P 25/00 (2018.01); A61P 29/00 (2018.01)]

25 Claims

1. A method of treating a subject having post-acute sequelae of COVID-19 (PASC), wherein the subject has one or more symptoms or signs selected from the group consisting of fatigue, myalgia, fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), idiopathic pulmonary fibrosis, confusion, muscle dysfunction, mitochondrial dysfunction, dyspnea after exertion, postural orthostatic tachycardia syndrome, tachycardia, mood disorders, and depression, comprising administering to the subject:

a) a leucine (L)-amino acid or salt thereof;

b) an arginine (R)-amino acid or salt thereof;

c) a glutamine (Q)-amino acid or salt thereof; and

d) N-acetylcysteine (NAC) or a salt thereof.